PT - JOURNAL ARTICLE AU - CM Schooling AU - JV Zhao AU - SL Au Yeung AU - GM Leung TI - Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK Biobank AID - 10.1101/2020.01.14.20017400 DP - 2020 Jan 01 TA - medRxiv PG - 2020.01.14.20017400 4099 - http://medrxiv.org/content/early/2020/01/16/2020.01.14.20017400.short 4100 - http://medrxiv.org/content/early/2020/01/16/2020.01.14.20017400.full AB - Background Statins appear to have pleiotropic effects, for reasons that are not well understood. We examined whether specifically statins, of the major lipid modifiers, operate on ischemic heart disease (IHD) via testosterone. As a validation, we assessed whether a drug (anakinra) that unexpectedly likely increases IHD also operates via testosterone.Methods We conducted a sex-specific univariate and multivariable Mendelian randomization study in the UK Biobank, including 179918 men (25410 IHD cases) and 212080 women (12511 IHD cases), using established genetic predictors of the effects of major lipids modifiers and anakinra.Results Of the three lipid modulations considered, statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe, only genetically predicted effects of statin use in men affected testosterone (−0.26 effect size testosterone per effect size (of low-density lipoprotein cholesterol), 95% confidence interval (CI) −0.39 to −0.13). The genetically predicted effect of statin use on IHD in men was partially mediated by testosterone (odds ratio (OR) 0.54 per effect size (of low-density lipoprotein cholesterol), 95% confidence interval (CI) 0.38 to 0.79, OR 0.67, 95% CI 0.38 to 1.02 after allowing for testosterone). The genetically predicted effect of anakinra use also affected testosterone (0.04 per effect size (of IL-1Ra), 95% CI 0.02 to 0.06), and increased IHD in men.Conclusions Statins may partially operate via testosterone in men, possibly contributing to pleiotropic effects. Anakinra operating testosterone may also explain its unexpected effects. Our findings could facilitate the development of new interventions for cardiovascular diseases and highlight the importance of sex-specific investigations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was recieved for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study only used data publicly available or available on request